Zydus Lifesciences Performance
52 Week Range
- Open Price
- Previous Close
Start SIP in Zydus LifesciencesStart SIP
Zydus Lifesciences Investment Rating
Zydus Lifesciences has an operating revenue of Rs. 16,433.50 Cr. on a trailing 12-month basis. An annual revenue growth of 7% is good, Pre-tax margin of 19% is great, ROE of 26% is exceptional. The company has a reasonable debt to equity of 2%, which signals a healthy balance sheet. The stock from a technical standpoint is comfortably placed above its key moving averages, around 10% and 21% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 3% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 74 which is FAIR indicating the recent price performance, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 94 indicates it belongs to a poor industry group of Medical-Generic Drugs and a Master Score of B is close to being the best. Overall, the stock is lagging behind in some of the technical parameters, but great earnings make it a stock to examine in more detail.
|Indicator||Dec 2022||Sep 2022||Jun 2022||Mar 2022|
|Oper Rev Qtr Cr||2,087||2,217||1,981||1,919|
|Operating Expenses Qtr Cr||1,628||1,720||1,437||1,562|
|Operating Profit Qtr Cr||459||679||544||458|
|Depreciation Qtr Cr||122||124||123||123|
|Interest Qtr Cr||89||64||41||42|
|Tax Qtr Cr||129||149||101||100|
|Net Profit Qtr Cr||256||451||332||247|
Zydus Lifesciences Technicals
EMA & SMA
- Bullish Moving Average
- Bearish Moving Average
- 20 Day
- 50 Day
- 100 Day
- 200 Day
- 20 Day
- 50 Day
- 100 Day
- 200 Day
Zydus Lifesciences Resistance and Support
|MACD Single Line||3.68|
Zydus Lifesciences Delivery and Volume
|Period||NSE + BSE Volume Avg||NSE + BSE Delivery Volume Avg||NSE + BSE Delivery Volume %|
Zydus Lifesciences Result Highlights
Zydus Lifesciences Synopsis
NSE-Medical-Generic DrugsZydus Lifesciences is involved in the business activities of Manufacture of medicinal substances used in the manufacture of pharmaceuticals: antibiotics, endocrine products, basic vitamins; opium derivatives; sulpha drugs; serums and plasmas; salicylic acid, its salts and esters; glycosides and vegetable alkaloids; chemically pure suger etc.. Company’s Total Operating Revenue is Rs. 7981.90 Cr. and Equity Capital is Rs. 102.40 Cr. for the Year ended 31/03/2022. Zydus Lifesciences Ltd. is a Public Limited Listed company incorporated on 15/05/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC025878 and registration number is 025878.
|Shares in Float||25.31|
|No of funds||218|
|U/D Vol ratio||1.8|
|LTDebt / Equity||1|
|Foreign Portfolio Investors||2.52%||2.61%||2.86%|
|Financial Institutions/ Banks||0.01%|
Zydus Lifesciences Management
|Mr. Pankaj R Patel||Chairman|
|Dr. Sharvil P Patel||Managing Director|
|Mr. Ganesh N Nayak||Executive Director|
|Mr. Bhadresh K Shah||Independent Director|
|Mr. Mukesh M Patel||Non Executive Director|
|Mr. Nitin R Desai||Independent Director|
|Ms. Dharmishtaben N Raval||Independent Woman Director|
|Ms. Apurva S Diwanji||Independent Director|
Zydus Lifesciences Forecast
Zydus Lifesciences Corporate Action
Zydus Lifesciences FAQs
What is Share Price of Zydus Lifesciences ?
Zydus Lifesciences share price is ₹479 As on 07 February, 2023 | 16:32
What is the Market Cap of Zydus Lifesciences ?
The Market Cap of Zydus Lifesciences is ₹48530.1 Cr As on 07 February, 2023 | 16:32
What is the P/E ratio of Zydus Lifesciences ?
The P/E ratio of Zydus Lifesciences is 23.5 As on 07 February, 2023 | 16:32
What is the PB ratio of Zydus Lifesciences ?
The PB ratio of Zydus Lifesciences is 2.5 As on 07 February, 2023 | 16:32
What were the company's most recent reported sales and net income?
Zydus Lifesciences Ltd. recorded a net income of INR 15,265.20 crores in FY22
What is the future of the company's shares?
Zydus Lifesciences Ltd. stock is a good option for long-term investment since the shares are ripe for buying right now.